JUBILANT INGREVIA Latest Share Price (JUBLINGREA)
TODAY IN ONE LINE
JUBLINGREA dropped 4.3% on above-average volume (4.1x avg), lagging Nifty's 1.1% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹8,967.53 Cr., it trades at a P/E of 25.58. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
JUBILANT INGREVIA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 16.1% YoY
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.28x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest JUBILANT INGREVIA News
What changed recently?
Recent events, corporate actions, and announcements.
JUBILANT INGREVIA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for JUBILANT INGREVIA, framed against the sector median so the premium or discount is obvious at a glance.
JUBILANT INGREVIA trades at a P/E of 25.58× and P/B of 2.70×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
JUBILANT INGREVIA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for JUBILANT INGREVIA — derived from the latest tape, not yesterday's close.
JUBILANT INGREVIA last traded at ₹567.85 with an intraday range of ₹561.85–₹595 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹567.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 654.25 | +86.40 | +15.22% |
| R3 | 621.10 | +53.25 | +9.38% |
| R2 | 608.05 | +40.20 | +7.08% |
| R1 | 587.95 | +20.10 | +3.54% |
| PIVOT | 574.90 | 7.05 | 1.24% |
| CURRENT | 567.85 | — | — |
| S1 | 554.80 | -13.05 | -2.30% |
| S2 | 541.75 | -26.10 | -4.60% |
| S3 | 521.65 | -46.20 | -8.14% |
| S4 | 488.50 | -79.35 | -13.97% |
JUBLINGREA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹580.65–₹595
Trading Below opening range, showing Bearishness
JUBILANT INGREVIA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for JUBILANT INGREVIA — consolidated or standalone — with margins, YoY growth and key ratios inline.
JUBILANT INGREVIA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹8,967.53 Cr. and reported EPS of ₹6.64.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 4,388 | 4,388 ▲ 0.0% |
| Sales Growth YoY %Derived | 5.04% | 5.04% |
| Other Income | 41 | 41 ▲ 0.0% |
| Total Income | 4,429 | 4,429 ▲ 0.0% |
| 2,295 | 2,295 ▲ 0.0% | |
| Gross ProfitDerived | 2,093 | 2,093 ▲ 0.0% |
| Gross Margin %Derived | 47.70% | 47.70% |
| 1,526 | 1,526 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 567 | 567 ▲ 0.0% |
| OPM %Derived | 12.92% | 12.92% |
| 212 | 212 ▲ 0.0% | |
| Profit Before Tax (PBT) | 370 | 370 ▲ 0.0% |
| 92 | 92 ▲ 0.0% | |
| Effective Tax %Derived | 24.83% | 24.83% |
| Total Profit for Period | 278 | 278 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 278 | 278 ▲ 0.0% |
| Net Profit Margin %Derived | 6.33% | 6.33% |
| PAT Growth YoY %Derived | 10.65% | 10.65% |
| Earnings Per Share (EPS ₹) | 17.45 | 17.45 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Share of Profit from Associates/JVs | -0 | -0 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 20 | 20 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 4,059 | 4,059 ▲ 0.0% |
| Material Cost % of RevenueDerived | 47.96% | 47.96% |
| Employee Cost % of RevenueDerived | 9.70% | 9.70% |
| Other Cost % of RevenueDerived | 25.08% | 25.08% |
| Interest Coverage (x)Derived | 7.97x | 7.97x |
| Period | Mar 2021 | Jun 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 684 | 684 ▲ 0.0% | 4,949 ▲ 623.5% | 4,949 ▲ 0.0% | 4,773 ▼ 3.6% | 4,773 ▲ 0.0% | 4,136 ▼ 13.3% | 4,136 ▲ 0.0% | 4,178 ▲ 1.0% | 4,178 ▲ 0.0% | 4,388 ▲ 5.0% | 4,388 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 623.45% | — | -3.57% | -3.57% | -13.34% | -13.34% | 1.01% | 1.01% | 5.04% | 5.04% | |
| Other Income | 3 | 3 ▲ 0.0% | 31 ▲ 1111.2% | 31 ▲ 0.0% | 33 ▲ 6.0% | 33 ▲ 0.0% | 35 ▲ 5.8% | 35 ▲ 0.0% | 38 ▲ 7.1% | 38 ▲ 0.0% | 41 ▲ 7.2% | 41 ▲ 0.0% | |
| Total Income | 687 | 687 ▲ 0.0% | 4,981 ▲ 625.3% | 4,981 ▲ 0.0% | 4,806 ▼ 3.5% | 4,806 ▲ 0.0% | 4,171 ▼ 13.2% | 4,171 ▲ 0.0% | 4,215 ▲ 1.1% | 4,215 ▲ 0.0% | 4,429 ▲ 5.1% | 4,429 ▲ 0.0% | |
370 | 370 ▲ 0.0% | 2,794 ▲ 655.3% | 2,794 ▲ 0.0% | 2,582 ▼ 7.6% | 2,582 ▲ 0.0% | 2,143 ▼ 17.0% | 2,143 ▲ 0.0% | 2,107 ▼ 1.6% | 2,107 ▲ 0.0% | 2,295 ▲ 8.9% | 2,295 ▲ 0.0% | ||
| Gross ProfitDerived | 314 | 314 ▲ 0.0% | 2,155 ▲ 586.0% | 2,155 ▲ 0.0% | 2,191 ▲ 1.7% | 2,191 ▲ 0.0% | 1,993 ▼ 9.0% | 1,993 ▲ 0.0% | 2,070 ▲ 3.9% | 2,070 ▲ 0.0% | 2,093 ▲ 1.1% | 2,093 ▲ 0.0% | |
| Gross Margin %Derived | 45.92% | 45.92% | 43.55% | 43.55% | 45.91% | 45.91% | 48.19% | 48.19% | 49.56% | 49.56% | 47.70% | 47.70% | |
197 | 197 ▲ 0.0% | 1,323 ▲ 571.6% | 1,323 ▲ 0.0% | 1,644 ▲ 24.2% | 1,644 ▲ 0.0% | 1,572 ▼ 4.4% | 1,572 ▲ 0.0% | 1,551 ▼ 1.3% | 1,551 ▲ 0.0% | 1,526 ▼ 1.6% | 1,526 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 117 | 117 ▲ 0.0% | 832 ▲ 610.2% | 832 ▲ 0.0% | 547 ▼ 34.2% | 547 ▲ 0.0% | 421 ▼ 23.0% | 421 ▲ 0.0% | 519 ▲ 23.3% | 519 ▲ 0.0% | 567 ▲ 9.2% | 567 ▲ 0.0% | |
| OPM %Derived | 17.12% | 17.12% | 16.81% | 16.81% | 11.46% | 11.46% | 10.18% | 10.18% | 12.43% | 12.43% | 12.92% | 12.92% | |
16 | 16 ▲ 0.0% | 154 ▲ 838.2% | 154 ▲ 0.0% | 144 ▼ 6.9% | 144 ▲ 0.0% | 189 ▲ 31.4% | 189 ▲ 0.0% | 213 ▲ 12.9% | 213 ▲ 0.0% | 212 ▼ 0.8% | 212 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 77 | 77 ▲ 0.0% | 709 ▲ 816.1% | 709 ▲ 0.0% | 437 ▼ 38.4% | 437 ▲ 0.0% | 268 ▼ 38.7% | 268 ▲ 0.0% | 344 ▲ 28.4% | 344 ▲ 0.0% | 370 ▲ 7.7% | 370 ▲ 0.0% | |
23 | 23 ▲ 0.0% | 232 ▲ 908.4% | 232 ▲ 0.0% | 129 ▼ 44.4% | 129 ▲ 0.0% | 85 ▼ 34.4% | 85 ▲ 0.0% | 92 ▲ 9.1% | 92 ▲ 0.0% | 92 ▼ 0.6% | 92 ▲ 0.0% | ||
| Effective Tax %Derived | 29.76% | 29.76% | 32.76% | 32.76% | 29.59% | 29.59% | 31.66% | 31.66% | 26.90% | 26.90% | 24.83% | 24.83% | |
| Total Profit for Period | 54 | 54 ▲ 0.0% | 477 ▲ 776.9% | 477 ▲ 0.0% | 308 ▼ 35.5% | 308 ▲ 0.0% | 183 ▼ 40.5% | 183 ▲ 0.0% | 251 ▲ 37.3% | 251 ▲ 0.0% | 278 ▲ 10.6% | 278 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 54 | 54 ▲ 0.0% | 477 ▲ 776.9% | 477 ▲ 0.0% | 308 ▼ 35.5% | 308 ▲ 0.0% | 183 ▼ 40.5% | 183 ▲ 0.0% | 251 ▲ 37.3% | 251 ▲ 0.0% | 278 ▲ 10.6% | 278 ▲ 0.0% | |
| Net Profit Margin %Derived | 7.95% | 7.95% | 9.63% | 9.63% | 6.44% | 6.44% | 4.42% | 4.42% | 6.01% | 6.01% | 6.33% | 6.33% | |
| PAT Growth YoY %Derived | — | — | 776.95% | — | -35.50% | -35.50% | -40.52% | -40.52% | 37.33% | 37.33% | 10.65% | 10.65% | |
| Earnings Per Share (EPS ₹) | 3.41 | 3.41 ▲ 0.0% | 29.93 ▲ 777.7% | 29.93 ▲ 0.0% | 19.31 ▼ 35.5% | 19.31 ▲ 0.0% | 11.48 ▼ 40.5% | 11.48 ▲ 0.0% | 15.77 ▲ 37.4% | 15.77 ▲ 0.0% | 17.45 ▲ 10.7% | 17.45 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | -0 | -0 ▲ 0.0% | — ▲ 100.0% | — | 0 | 0 ▲ 0.0% | -0 ▼ 200.0% | -0 ▲ 0.0% | -0 ▼ 800.0% | -0 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 5 | 5 ▲ 0.0% | 96 ▲ 1819.3% | 96 ▲ 0.0% | 2 ▼ 97.5% | 2 ▲ 0.0% | 4 ▲ 46.3% | 4 ▲ 0.0% | 2 ▼ 49.3% | 2 ▲ 0.0% | 20 ▲ 1041.6% | 20 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 609 | 609 ▲ 0.0% | 4,272 ▲ 601.1% | 4,272 ▲ 0.0% | 4,369 ▲ 2.3% | 4,369 ▲ 0.0% | 3,904 ▼ 10.7% | 3,904 ▲ 0.0% | 3,872 ▼ 0.8% | 3,872 ▲ 0.0% | 4,059 ▲ 4.8% | 4,059 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 53.13% | 53.13% | 56.54% | 56.54% | 53.38% | 53.38% | 49.33% | 49.33% | 49.08% | 49.08% | 47.96% | 47.96% | |
| Employee Cost % of RevenueDerived | 7.17% | 7.17% | 6.61% | 6.61% | 7.20% | 7.20% | 9.28% | 9.28% | 10.01% | 10.01% | 9.70% | 9.70% | |
| Other Cost % of RevenueDerived | 21.64% | 21.64% | 20.13% | 20.13% | 27.25% | 27.25% | 28.73% | 28.73% | 27.13% | 27.13% | 25.08% | 25.08% | |
| Interest Coverage (x)Derived | 12.97x | 12.97x | 22.90x | 22.90x | 19.69x | 19.69x | 5.41x | 5.41x | 6.50x | 6.50x | 7.97x | 7.97x |
JUBILANT INGREVIA segment analysis : revenue and profit mix.
Disclosed business segments at JUBILANT INGREVIA with their share of revenue and profit, switchable between consolidated and standalone reporting.
JUBILANT INGREVIA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for JUBILANT INGREVIA.
Our AI distills the core fundamental drivers supporting JUBILANT INGREVIA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 33 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
JUBILANT INGREVIA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — JUBILANT INGREVIA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
JUBILANT INGREVIA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for JUBILANT INGREVIA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
JUBILANT INGREVIA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for JUBILANT INGREVIA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in JUBILANT INGREVIA stood at 55.1% of traded volume, against a 20-day average of 47.0%.
JUBILANT INGREVIA announcements: results, concalls, ratings, M&A.
Filings JUBILANT INGREVIA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
JUBILANT INGREVIA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 214 documents below.
General Updates
Jubilant Ingrevia Limited has informed the Exchange about General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Jubilant Ingrevia Limited has informed the Exchange about Schedule of meet
General Updates
Jubilant Ingrevia Limited has informed the Exchange about incorporation of wholly-owned subsidiary
Utilisation of Funds
Jubilant Ingrevia Limited has informed the Exchange about Utilisation of Funds
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Jubilant Ingrevia Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Investor decks & rating reports.
JUBILANT INGREVIA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue JUBILANT INGREVIA has declared, sequenced by announce and record date.
JUBILANT INGREVIA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
JUBILANT INGREVIA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in JUBILANT INGREVIA as reported to SEBI — buying and selling signals from the people who know the business best.
JUBILANT INGREVIA insider activity below tracks 51 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 23 Mar 2026 | buy | +10.0 K | ₹56.21 L | ₹562.09 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 20 Mar 2026 | buy | +25.0 K | ₹1.45 Cr. | ₹581.66 |
| Jubilant Ingrevia Employees Welfare Trust | Insider | 19 Mar 2026 | buy | +50.0 K | ₹2.89 Cr. | ₹578.86 |
About JUBILANT INGREVIA: business, sector, key facts.
What JUBILANT INGREVIA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
JUBILANT INGREVIA operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: JUBLINGREA, BSE: 543271.
Jubilant Ingrevia Limited (formerly Jubilant LSI Limited) is a global life sciences company operating across India, the United States, Europe, and China. The company's core business centers on the development, manufacture, and supply of a diverse range of specialty chemicals, nutrition & health solutions, and chemical intermediates. This multifaceted approach allows them to serve a wide spectrum of industries.
Their Specialty Chemicals segment is a significant contributor, offering a comprehensive portfolio including bio-pyridine and -picolines, fine chemicals, agrochemicals, and custom development and manufacturing services. This segment also encompasses solutions for microbial control, highlighting a focus on both the development of specific chemical compounds and the provision of tailored solutions to meet specific customer needs.
The Nutrition & Health Solutions segment focuses on the production and supply of ingredients and solutions for both human and animal nutrition. This involves a range of products, from vitamins (such as Vitamin B3 and B4) and minerals to premixes, antioxidants, and other specialized nutritional components. The company's expertise extends to providing solutions for stress regulation and enhancing egg quality in animal feed, demonstrating a commitment to various market segments within the nutrition sector.
The Chemical Intermediates segment provides essential building blocks for various industries. Their offerings include acetyls, specialty ethanol, and a wide array of pyridine derivatives with diverse functional groups (cyano, acetyl, amino, halo, alkyl, and aldehyde). This segment emphasizes the supply of fundamental chemicals that form the basis for many downstream applications.
In addition to product offerings, Jubilant Ingrevia provides comprehensive services, including route design, process development, optimization, and scale-up for commercial manufacturing of intermediates. This integrated approach differentiates them by offering end-to-end solutions, supporting clients throughout the entire process from initial concept to large-scale production.
Jubilant Ingrevia serves a diverse client base across pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial sectors. Their broad product and service portfolio combined with their global reach establishes them as a significant player in the life sciences industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AARTI INDUSTRIES (AARTIIND) Share PricePeer
- AARTISURF (AARTISURF) Share PricePeer
- ARCHEAN CHEMICAL IND (ACI) Share PricePeer
- AETHER INDUSTRIES (AETHER) Share PricePeer
- ALKALI (ALKALI) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about JUBILANT INGREVIA (JUBLINGREA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of JUBILANT INGREVIA (JUBLINGREA)?
The current share price of JUBILANT INGREVIA (JUBLINGREA) is ₹567.85. Today, the stock has declined by ₹25.75 (4.34%), trading in a range of ₹561.85 to ₹595.00. The stock opened at ₹594.40 with a trading volume of 10,90,163 shares.
02Is JUBILANT INGREVIA stock a good investment for long-term?
JUBILANT INGREVIA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹8,967.53 Cr., P/E ratio of 25.58, ROE of 10.15%, and ROCE of 10.19%. The dividend yield stands at 0.85%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of JUBILANT INGREVIA stock?
The 52-week high price of JUBILANT INGREVIA (JUBLINGREA) is ₹795.00, while the 52-week low is ₹537.30. Currently trading at ₹567.85, the stock is 5.69% above its 52-week low and 28.57% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy JUBILANT INGREVIA stock at the current price?
Whether to buy JUBILANT INGREVIA stock at ₹567.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.58 and P/B ratio of 2.7. Today's performance shows a loss of 4.34%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of JUBILANT INGREVIA and when is the next dividend?
JUBILANT INGREVIA offers a dividend yield of 0.85%, which means for every ₹100 invested at the current price of ₹567.85, you can expect to receive approximately ₹0.85 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of JUBILANT INGREVIA?
JUBILANT INGREVIA's key financial metrics include: P/E Ratio: 25.58, P/B Ratio: 2.7, ROE: 10.15%, ROCE: 10.19%, Dividend Yield: 0.85%, EPS: ₹6.64, Book Value: ₹196.27, and Debt-to-Equity: 0.28. The company's market cap stands at ₹8,967.53 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is JUBILANT INGREVIA stock performing today in the market?
JUBILANT INGREVIA stock opened at ₹594.40 and is currently trading at ₹567.85, showing a decline of ₹25.75 (4.34%). The intraday high is ₹595.00 and low is ₹561.85. The trading volume stands at 10,90,163 shares, indicating strong market participation today.
08What is the P/E ratio of JUBILANT INGREVIA and what does it indicate?
JUBILANT INGREVIA has a Price-to-Earnings (P/E) ratio of 25.58, which means investors are willing to pay 25.58 for every ₹1 of earnings. With an EPS of ₹6.64, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about JUBILANT INGREVIA (JUBLINGREA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.